Noxsano Animal Health Engages MFP to Raise Capital using New and Revolutionary SFS™ Program
Noxsano Animal Health (NAH), a veterinary wound care innovator spun out from Noxsano Inc., is preparing to raise capital through a Regulation A+ offering using Medical Funding Professionals’ new Secured Financed Services™(SFS) program. The capital raise will support the company’s expansion in sales, marketing, product development, and distribution of its nitric oxide-based wound care solutions for animals under the Restore by Noxsano® brand.
Regulation A+’s selling shareholders provision allows existing shareholders to sell a portion of their securities in the offering, creating a potential early liquidity event for Seed-stage backers that positions NAH for a broader base of investor engagement.
Medical Funding Professionals (MPF) is pleased to announce that Noxsano Animal Health has engaged MFP to implement the Capital Planning Valuation Strategy™ (CPVS) in preparation for the company’s Regulation A+ offering through MFP’s recently launched Secured Financed Services™ (SFS) program.
Noxsano Animal Health (NAH) is a pioneering veterinary technology company that spun out from Noxsano Inc late last year, with an exclusive focus on professional veterinary medical products under its Restore by Noxsano® brand, addressing chronic wounds, surgical wounds, burns, difficult infections and dermatological conditions in companion animals, equine, exotics, and livestock market sectors.
The company specializes in nitric oxide-based (NOx) wound care and infection solutions in animal markets. Noxsano’s proprietary technology delivers nitric oxide to tissues electrochemically, actively promoting tissue regeneration and providing superior infection control.
Noxsano’s technology has been validated through preclinical and veterinary clinical studies, demonstrating improved healing times of up to 50% and effective infection prevention and remediation against even resistant strain pathogens. Case studies on animals ranging from elephants to dwarf marmosets demonstrate the effectiveness of the patented technology, which can be seen at https://www.noxsano.com/case-study
“We have achieved a major milestone in veterinary wound care,” says Noxsano Inc Founder and CEO Alan Willey. “Our flagship wound pads and gels are transforming how wounds are treated in animals, with clinical trials showing up to 50% reduction in healing time, setting a new standard in veterinary wound care.”
Seeking funds to expand its sales, marketing, new product development, and distribution capabilities, Noxsano Animal Health, led by Noxsano Animal Health CEO Joe Ehrhard, is set to undergo its first public offering of securities via Regulation A+, a JOBS-Act exemption which allows private companies to raise up to $75 million per year online from accredited and non-accredited investors.
NAH has engaged a full team of industry professionals under the SFS™ program to manage the front-end buildout for the raise, including registered investment advisor Medical Funding Professionals, corporate legal counsel, and corporate finance and communications – collectively CPVS™. The SFS™ program will allow NAH to defer most of the up-front cost of services required to build a company-branded online capital fundraising platform, with accounts settled over 12-18 months as funds are raised from the offering.
“SFS™ is a truly groundbreaking approach to fundraising,” says Ehrhard. “It lets us get out of the gate and launch our offering for much less than what it would typically cost to execute while bringing in specialized resources to help drive the capital raise to a successful completion. Thanks to the CPVS™ team and their guidance we now have a clear, actionable roadmap for securing the funding we need to really drive our business forward.”
One unique feature of Regulation A+ is its selling shareholders provision, which allows existing shareholders to sell a portion of their shares in the offering alongside the company’s newly issued securities. This feature provides a quick path to liquidity for early investors, making it a compelling incentive during initial funding rounds prior to Reg A+. Noxsano Animal Health has a $1MM Seed round in progress and plans to launch a Regulation D (506c) bridge round offering in preparation for their larger Regulation A+ round later this year.
“We are thrilled to be working with Noxsano Animal Health,” says Medical Funding Professionals CEO Stephen Brock. “They have the potential to revolutionize the veterinary wound care market, and we look forward to partnering with them for the next stage of their journey.”
About Noxsano Animal Health
Noxsano Inc was founded by former P&G scientists in 2020, with a mission to revolutionize wound care using exogenous nitric oxide. Noxsano developed a patented, novel approach to nitric oxide delivery that enhances healing outcomes in animals. The company’s technology has been validated through preclinical and veterinary studies, demonstrating faster healing times and effective infection prevention and remediation. Noxsano Animal Health now operates independently from Noxsano Inc.’s human health focus to optimize investment and market penetration strategies in their respective markets.
Contact
Joseph Ehrhard, CEO
• Calendly: Schedule a Meeting
• Email: joe@noxsano.com
• Website: https://noxsano.com
About Medical Funding Professionals
Medical Funding Professionals (MFP) is a registered investment advisory located in Nevada. MFP provides funding solutions for short- and long-term startups as well as mid-market private and public companies in the biotech, medtech, life sciences, and pharmaceuticals industries through Reg A+, Reg CF, and Reg D 506(c) funding as well as government grants and other non-dilutive funding sources such as cooperative agreements and other non-traditional government-backed strategies. MFP has 22 years of experience in the capital markets with over a decade securing funding for medical and life sciences companies. MFP’s in-depth knowledge of capital raising rules and regulations, including Reg A+, Reg CF, Reg D, OTC markets, reverse mergers, NASDAQ, FINRA, SEC, and Sarbanes Oxley Act Compliance, has proven invaluable in helping clients navigate the complex fundraising process and raise capital efficiently.
About Secured Financed Services™ (SFS)
SFS™ is an invitation only, capital planning, secured project finance model derived from a combination of financing strategies available to the best-of-the-best pharma, biotech, and life sciences companies with solid management teams.
SFS has three key pillars:
- Defer up to 53% of the fixed costs to build a company-branded online capital raising platform at a time when the need for cash is most critical.
- Cost-effectively raise capital concurrently from sophisticated investors and a broader more diverse pool of investors – namely investment dollars from retail investors.
- Settle invoices over 12-18 months as cash becomes available from the capital raised.
“Beginning in the mid-90s, everyone raced to build a website to market and sell goods and services, now with the JOBS Act , the play is taking those websites to the next level and building company branded platforms to market and sell their stock, notes, bonds and other securities, but they need a cost-effective strategy to do that – SFS,” says Medical Funding Professionals CEO Stephen Brock.
Regulation A+ Disclaimer
This communication may be deemed to be a solicitation of interest under Regulation A under the Securities Act of 1933, in which case the following apply:
- No money or other consideration is being solicited, and if sent in response, will not be accepted;
- No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date;
- A person’s indication of interest involves no obligation or commitment of any kind; and
- An offering statement, which would include a preliminary offering circular, has not yet been filed with the SEC.
If you’d like to learn more about our new and revolutionary SFS™ model and how we can help you achieve your capital raising goals for your medtech, pharma, biotech, or life science company, you can schedule a time with me here by clicking on this link “Schedule a SFS Call” and choosing a specific date and time that works for you.
Contact
Stephen Brock, CEO
• Calendly: Schedule a Meeting
• Email: stephen.brock@medicalfundingpro.com
• Website: https://medicalfundingpro.com/
Disclaimer:
Medical Funding Professionals (MFP) is a registered investment advisor located in Nevada. MFP and its representatives are in compliance with the current filing requirements imposed upon registered investment advisors by those jurisdictions in which MFP maintains clients. MFP may only transact business in those states in which it is registered or qualifies for an exemption or exclusion from registration requirements. None of the information contained in this communication constitutes an offer (or solicitation of an offer) to buy or sell any securities, to make any investment, or to participate in any particular investment, offering, or trading strategy. The information and materials provided herein,
whether or not provided on MFP emails, website/webpages, on third party websites, in marketing materials, newsletters or any form of publication are provided for general information and educational purposes, and do not constitute legal, tax or investment advice. Capital Planning Valuation Strategy, CPVS, CPVS Plus, Secured Financed Services and SFS are trademarks of Medical Funding Professionals, LLC.
